<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00763568</url>
  </required_header>
  <id_info>
    <org_study_id>RM01-3037</org_study_id>
    <nct_id>NCT00763568</nct_id>
  </id_info>
  <brief_title>4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C</brief_title>
  <official_title>Study of a 4-Week Lead-In With Nitazoxanide Followed By 36 Weeks of Nitazoxanide Plus Peginterferon Alfa-2a in the Treatment of Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Romark Laboratories L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Romark Laboratories L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if taking nitazoxanide alone for 4 weeks followed
      by 36 weeks of nitazoxanide plus peginterferon is superior to peginterferon plus ribavirin
      (standard of care) for 48 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virologic response</measure>
    <time_frame>24 weeks after the end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>End of treatment virologic response</measure>
    <time_frame>At the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early virologic response</measure>
    <time_frame>After 12 weeks of combination therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapid virologic response</measure>
    <time_frame>After 4 weeks of combination therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT normalization</measure>
    <time_frame>24 weeks after the end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Nitazoxanide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.</description>
    <arm_group_label>Nitazoxanide</arm_group_label>
    <other_name>Alinia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.</description>
    <arm_group_label>Nitazoxanide</arm_group_label>
    <other_name>PEGASYS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis C

        Exclusion Criteria:

          -  Previously failed to respond to at least 12 weeks of peginterferon plus ribavirin
             combination therapy.

          -  Unable to take oral medication.

          -  Females who are either pregnant, breast-feeding or not using birth control.

          -  Males whose female partners are pregnant or plan to become pregnant.

          -  Other causes of liver disease (for example, autoimmune hepatitis, decompensated liver
             disease).

          -  Patients with HIV, HAV, HBV or HDV.

          -  Patients with a history of alcoholism or with an alcohol consumption of more than 40
             grams per day.

          -  Patients with hemoglobinopathies (for example, thalassemia major, sickle-cell anemia).

          -  History of hypersensitivity or intolerance to nitazoxanide or peginterferon.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asem Elfert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tanta University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Digestive Disease Center</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2008</study_first_posted>
  <last_update_submitted>September 26, 2008</last_update_submitted>
  <last_update_submitted_qc>September 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Romark Laboratories, L.C.</name_title>
    <organization>Romark Laboratories, L.C.</organization>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Viral hepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

